Abstracts tagged "Tumor necrosis factor (TNF)"

Abstract Number: 0585 • ACR Convergence 2024
Cycling to TNFi vs. Switching to IL-17Ai After a First TNFi Discontinuation Among Patients with PsA and axSpA: The CorEvitas PsA/SpA Registry
Alexis Ogdie¹, Nicole Middaugh², Maya Marchese², Jessica A Walsh³, Natalia Bello⁴, Jeffrey Lisse⁴, Andris Kronbergs⁵, Elsie Grace⁶, Marcus Ngantcha⁴ and Philip Mease⁷, ¹Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ²CorEvitas, LLC, Waltham, MA, ³Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Eli Lilly, Indianapolis, IN, ⁶Eli Lilly and Company, Indianapolis, ⁷Swedish Medical Center/Providence St. Joseph Health; University of Washington School of Medicine, Seattle, WA
Background/Purpose: Treatment guidelines recommend tumor necrosis factor inhibitors (TNFi) and interleukin-17A inhibitors (IL-17Ai) as options for patients with PsA or axSpA with persistent disease activity…
Abstract Number: 0604 • ACR Convergence 2024
Secular Trends in Biologic Prescribing for Psoriasis and Psoriatic Arthritis, 2014-2024
Mahum Mirza¹, Jean Liew², Michael Putman³ and Shikha Singla¹, ¹Medical College of Wisconsin, Milwaukee, WI, ²Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ³The Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Treatment options for psoriasis or psoriatic arthritis (PsA) have expanded in the past decade. Secular trends in biologic disease modifying antirheumatic drug (bDMARD) prescribing…
Abstract Number: 0880 • ACR Convergence 2024
Investigating the SRPK-1-VEGF-A Alternative Splicing Pathway AsaTherapeutic Target in Arthritis
Charles Besidonne¹, Andrew Benest¹, Kim Chisholm¹, Jonathan Morris², Lucy Donaldson³, Jeanette Woolard⁴ and David Bates¹, ¹University of Nottingham, Nottingham, United Kingdom, ²University of New South Wales, New South Wales, New South Wales, Australia, ³Versus Arthritis UK, Nottingham, United Kingdom, ⁴University of Nottingham, Nottingham, England, United Kingdom
Background/Purpose: Alternative pre-mRNA splicing of Vascular Endothelial Growth Factor-A (VEGF-A) produces pro-angiogenic (VEGF-Axxxa) or anti-angiogenic (VEGF-Axxxb) isoforms that contribute to angiogenesis in inflammatory arthritis. Isoform…
Abstract Number: 0905 • ACR Convergence 2024
High-Throughput Proteomic Profiling of Sera as a Non-Invasive Method for Identifying Lupus Nephritis Subtypes
Rufei Lu¹, Andrea Fava², Benjamin Jones³, Peter Izmirly⁴, Jennifer Anolik⁵, Chaim Putterman⁶, David Wofsy⁷, Matthias Kretzler⁸, Celine Berthier⁹, E. Steve Woodle¹⁰, Michael Weisman¹¹, Mariko Ishimori¹², The Accelerating medicines Partnership: RA/SLE Network¹³, Betty Diamond¹⁴, Jill Buyon¹⁵, Michelle Petri¹⁶, Richard Furie¹⁷, Judith James¹³ and Joel Guthridge¹³, ¹University of California San Francisco, San Bruno, CA, ²Divison of Rheumatology, Johns Hopkins University, Baltimore, MD, ³Oklahoma State University, Oklahoma City, OK, ⁴New York University Grossman School of Medicine, New York, NY, ⁵University of Rochester Medical Center, Rochester, NY, ⁶Albert Einstein College of Medicine, Safed, Israel, ⁷University of California San Francisco, SF, CA, ⁸University of Michigan, Ann Arbor, MI, USA, Ann Arbor, MI, ⁹University of Michigan, Ann Arbor, MI, ¹⁰University of Cincinnati College of Medicine, Cincinnati, OH, USA, Cinncinnati, OH, ¹¹Stanford University, Los Angeles, CA, ¹²Cedars-Sinai Health System, Los Angeles, CA, ¹³Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁴The Feinstein Institutes for Medical Research, Manhasset, NY, ¹⁵NYU Grossman School of Medicine, New York, NY, ¹⁶Johns Hopkins University School of Medicine, Timonium, MD, ¹⁷Northwell Health, Manhasset, NY
Background/Purpose: Lupus nephritis (LN) treatment decisions are typically informed using histopathological classification based on the International Society of Nephrology/Renal Pathology Society (ISN/RPS) and NIH activity…
Abstract Number: 0936 • ACR Convergence 2024
Schnurri-3 Inhibition Protects from NF-kB-induced Bone Loss in Inflammatory Arthritis
Priyanka Kushwaha¹, Catherine Manning², Tadatoshi Sato³, Yeon-Suk Yang³, Jae-Hyuck Shim⁴ and Ellen Gravallese⁵, ¹Department of Medicine/Division of Rheumatology, Inflammation and Immunity, Brigham and Women’s Hospital, Boston, MA, ²Brigham and Women's Hospital, Dedham, MA, ³Department of Medicine/Division of Rheumatology, Horae Gene Therapy Center, University of Massachusetts Chan Medical School, Worcester, MA, ⁴University of Massachusetts, Worcester, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Chestnut Hill, MA
Background/Purpose: In rheumatoid arthritis (RA), production of TNF promotes osteoclast activity and inhibits osteoblasts (OBs) and bone healing. Schnurri-3 (SHN3) is a potent suppressor of…
Abstract Number: 1401 • ACR Convergence 2024
Risk of Malignancy with TNF-α Inhibitors in Patients with Rheumatoid Arthritis
Omair Khan¹, Syed Mujtaba Baqir², Azka Naeem², Muhammad Hashim khan², Tharun Shyam², Kseniya Slobodyanyuk³ and Anastasia Slobodnick⁴, ¹Maimonides Medical Center, Council Bluffs, IA, ²Maimonides Medical Center, Brooklyn, NY, ³Maimonides Medical Center, Manhattan, NY, ⁴Northwell, Staten Island, NY
Background/Purpose: Rheumatoid arthritis (RA) is associated with various comorbidities and complications among which cancer has been highlighted in literature. This cancer risk has been attributed…
Abstract Number: 1840 • ACR Convergence 2024
Synovial Resident Memory T Cell Formation During Inflammation Requires Cell Contact with Fibroblast-Like Synoviocytes
Yusuke Miyashita¹, Yang Yang¹, Madison Mangin¹, Maryrose Hahn², Kevin Wei³, Peter Nigrovic⁴ and Margaret Chang¹, ¹Boston Children's Hospital, Boston, MA, ²Boston Children's Hospital, Georgetown, MA, ³Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁴Boston Children's Hospital, Brookline, MA
Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by recurrent inflammation in the same joints, a feature termed joint-specific memory. We previously demonstrated…
Abstract Number: 2042 • ACR Convergence 2024
Overview of Lung Manifestations in Sarcoidosis and Various Treatment Approaches at a University Center
Aleeza Qamar¹, Upasana Agrawal², Karan Sachdeva³, Zara Hassan⁴, Alex Zamora¹, Syeda Nida⁵, Sarwat Umer¹, Samina Hayat¹ and Kinza Muzaffar⁶, ¹LSU Health-Shreveport, Shreveport, ²LSU Health, Shreveport, Shreveport, LA, ³Louisiana state university health shreveport LA, Shreveport, ⁴Louisiana State University Health Sciences, Shreveport, LA, ⁵LSU Healh-Shreveport, Shreveport, ⁶LSU HEALTH SHREVEPORT, SHREVEPORT, LA
Background/Purpose: Sarcoidosis is a disease occurring in the form of non-caseating granulomas, with unclear etiology and multi-system manifestations. Pulmonary involvement in sarcoidosis is a cardinal…
Abstract Number: 2275 • ACR Convergence 2024
Cardiovascular and Cancer Safety of JAKi Compared to TNFi in Patients with Rheumatoid Arthritis: Results from a National Registry of Advanced Therapies
Lucia Otero-Varela¹, Carlos Sanchez-Piedra², Elena Rabadán Rubio³, Juan Camilo Sarmiento-Monroy⁴, Chamaida Plasencia-Rodríguez⁵, Diana Sueiro⁶, Olga Martinez⁷, Noemí Busquets Pérez⁸, Mercedes Freire González⁹, Fernando Sánchez-Alonso¹⁰, José María Álvaro-Gracia¹¹ and Isabel Castrejon¹², and BIOBADASER group, ¹Spanish Society of Rheumatology, Madrid, Spain, ²Agencia de Evaluación de Tecnologías Sanitarias, Instituto de Salud Carlos III, Madrid, Spain, ³Hospital Universitario Principe de Asturias, Alcalá de Henares, Madrid, Spain, ⁴Hospital Clínic Barcelona, Barcelona, Spain, ⁵Hospital Universitario La Paz, MADRID, Spain, ⁶Complexo Hospitalario Universitario de Ourense, Ourense, Spain, ⁷Hospital Universitario de Salamanca, Zamora, Spain, ⁸HOSP. GENERAL DE GRANOLLERS, GRANOLLERS, Spain, ⁹Complexo Hospitalario Universitario de A Coruña, La coruna, Galicia, Spain, ¹⁰Sociedad Española de Reumatología, Madrid, Spain, ¹¹Hospital Gregorio Marañón, Madrid, Spain, ¹²Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Preliminary results from the ORAL Surveillance clinical trial showed an increase in the risk of major adverse cardiovascular events (MACE) and malignancies in patients…
Abstract Number: 2539 • ACR Convergence 2024
Telocytes Integrated into Mast Cells and Joint-Draining Lymphatic Vessels Potentially Regulate Lymphatic Clearance
Yue Peng¹, H. Mark Kenney², Karen Bentley¹, Lianping Xing³, Benjamin Korman⁴, Christopher Ritchlin⁵ and Edward Schwarz¹, ¹University of Rochester School of Medicine and Dentistry, Rochester, NY, ²University of Rochester School of Medicine and Dentistry, Henrietta, NY, ³University of Rochester School of Medicine and Dentistry, Webster, NY, ⁴University of Rochester, Rochester, NY, ⁵Department of Medicine, Allergy, Immunology, and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY
Background/Purpose: Rheumatoid arthritis (RA) patients and TNF-transgenic mice have lymphatic dysfunction (1). Recently, we showed mast cells involvement, as genetic ablation and drug inhibition decreased…
Abstract Number: 0256 • ACR Convergence 2024
Anti-TNF Therapy as a Potential Risk of Leishmania Infections
Gloria Albaladejo Paredes¹, Alicia Pérez González¹, Esther Monleón Acosta¹, Jose Andrés Rodríguez Fernández¹, Pedro José Manuel Hernández¹, Carlos Fernández Díaz¹, María Rosario Oliva Ruíz¹, Jose María Andreu Ubero², Paloma Valentina Castillo Dayer², Edgar Soriano Navarro³, David Pérez Parra⁴, Claudia Alejandra Capozzi², María Rocío González Molina⁵, José Francisco Orts Paco⁶, José Pablo Serrano Serra⁶ and Vicente Cogolludo Campillo², ¹Hospital Universitario Santa Lucía, CARTAGENA, Spain, ²Hospital Universitario Santa Lucía, Cartagena, Murcia, Spain, ³Hospital Universitario Santa Lucía, Murcia, Murcia, Spain, ⁴Hospital Universitario Santa Lucía, Murcia, ⁵Hospital Reina Sofía, Murcia, Murcia, Spain, ⁶Hospital Universitario Reina Sofía, Murcia, Murcia, Spain
Background/Purpose: Leishmaniasis is an infectious disease caused by protozoon that occurs endemically in the Mediterranean Basin and South America and can affects to travellers to…
Abstract Number: 0401 • ACR Convergence 2024
Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment
Cora Sears¹, Cassandra Muir¹, Timothy Brandon¹, Polly Ferguson², Colleen Correll³, Margalit Rosenkranz⁴, Kevin Baszis⁵, Tzielan Lee⁶, Edward Oberle⁷, Matthew Stoll⁸, Kathryn Cook⁹, Eyal Muscal¹⁰, Hemalatha Srinivasalu¹¹, Daniel Lovell¹², Sampath Prahalad¹³, Michal Cidon¹⁴, Evan Mulvihill¹⁵, Marisa Klein-Gitelman¹⁶, Daniel Kingsbury¹⁷, Jennifer Cooper¹⁸, Natalie Rosenwasser¹⁹, Erin Treemarcki²⁰, Joyce Chang²¹, Stacey Tarvin²², Heather Walters²³, Michael Shishov²⁴, Lisa Buckley²⁵, Mary Toth²⁶, Ashley Cooper²⁷, Rui Xiao²⁸, Emily Neu²⁹, Melanie Kohlheim³⁰, Jenny Leal³¹, Kweli Archie³², English Holland³³, Miles Holland³⁴, Aamena Hameed³⁵, Asad Khan³⁶, Lynn Murphy³⁷, Sean Murphy³⁸, Justin Neu²⁹, Rachel Richmond³⁹, Dylan Suplee⁴⁰, Theresa Suplee⁴¹, Dawn Wiley⁴² and Pamela Weiss⁴³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²University of Iowa Carver College of Medicine, Iowa City, IA, ³University of Minnesota, Minneapolis, MN, ⁴UPMC Children's Hospital of Pittsburgh, Pittsburgh, PA, ⁵Washington Univ in St. Louis School of Medicine, St Louis, MO, ⁶Stanford University School of Medicine, Palo Alto, CA, ⁷Nationwide Children's Hospital, Columbus, OH, ⁸University of Alabama at Birmingham, Birmingham, AL, ⁹Akron Children's Hospital, Akron, OH, ¹⁰Baylor College of Medicine, Houston, TX, ¹¹Children's National Hospital, Washington, DC, ¹²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹³Emory + Children's Pediatric Institute, Atlanta, GA, ¹⁴Children's Hospital of Los Angeles, Los Angeles, CA, ¹⁵Nemours/A.I.duPont Hospital for Children, Wilmington, DE, ¹⁶Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ¹⁷Legacy Health, Portland, OR, ¹⁸University of Colorado/Children's Hospital Colorado, Aurora, CO, ¹⁹Seattle Children's Hospital, Seattle, WA, ²⁰University of Utah, Salt Lake City, UT, ²¹Boston Children's Hospital, Boston, MA, ²²Indiana University School of Medicine, Indianapolis, IN, ²³Northwell Health, New Hyde Park, NY, ²⁴Phoenix Children's Hospital, Phoenix, AZ, ²⁵Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, TN, ²⁶Nemours Foundation, Orlando, FL, ²⁷Children's Mercy Kansas City, Kansas City, MO, ²⁸University of Pennsylvania, Philadelphia, PA, ²⁹Parent Partner, Sidney, OH, ³⁰Parent Partner, Granville, OH, ³¹Parent Partner, Columbus, OH, ³²Parent Partner, Philadelphia, PA, ³³Parent Partner, Williamsburg, VA, ³⁴Patient Partner, Williamsburg, VA, ³⁵Parent Partner, Franklin Park, NJ, ³⁶Patient Partner, Franklin Park, NJ, ³⁷Parent Partner, Haddon Heights, NJ, ³⁸Patient Partner, Haddon Heights, NJ, ³⁹Parent Partner, Albuquerque, NM, ⁴⁰Patient Partner, Maple Shade, NJ, ⁴¹Parent Partner, Maple Shade, NJ, ⁴²Parent Partner, Downingtown, PA, ⁴³Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: Inactive disease is the goal for youth with spondyloarthritis (SpA). Many patients are interested in stopping medications after inactive disease is achieved. The risk…
Abstract Number: 0457 • ACR Convergence 2024
Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis
Joshua Baker¹, George Reed², Geoffrey Thiele³, Dimitrios Pappas⁴, christina Charles-Schoeman⁵, Monica Guma⁶, Leslie Harrold⁷, Jeffrey Curtis⁸ and Joel Kremer⁹, ¹Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ²University of Massachusetts Chan Medical School, Worcester, MA, ³University of Nebraska Medical Center, Omaha, NE, ⁴CorEvitas, New York, NY, ⁵UCLA Medical Center, Santa Monica, CA, ⁶UCSD, La Jolla, CA, ⁷CorEvitas, Northborough, MA, ⁸University of Alabama at Birmingham, Hoover, AL, ⁹The Corrona Research Foundation, Delray Beach, FL
Background/Purpose: While BMI has been associated with response to therapy in several studies in rheumatoid arthritis (RA), it is not a comprehensive measure of the…
Abstract Number: 0529 • ACR Convergence 2024
Discontinuation of Targeted Disease-Modifying Antirheumatic Agents in Older Patients with Rheumatoid Arthritis: Retrospective Analysis of Medicare Data
Yinan Huang¹, Shadi Bazzazzadehgan², Sebastian Bruera³ and Sandeep Agarwal³, ¹University of Mississippi School of Pharmacy, Oxford, MS, ²University of Mississippi School of Pharmacy, Oxford, ³Baylor College of Medicine, Houston
Background/Purpose: Individuals with rheumatoid arthritis (RA) may discontinue b/tsDMARDs due to treatment failure, adverse events or costs. Little is known about b/tsDMARDs discontinuation among Medicare…
Abstract Number: 1333 • ACR Convergence 2023
Rheumatoid Arthritis-associated Lymphoproliferative Disorders: A Multi-center Analysis of Clinical Outcomes and Evaluation of Anti-rheumatic Drugs After LPD Onset
YOSHIHIKO HOSHIDA¹, Atsuko Tsujii², SHIRO OHSHIMA³, YUKIHIKO SAEKI³, MASATO YAGITA⁴, TOMOYA MIYAMURA⁵, Masao Katayama⁶, TOMONORI KAWASAKI⁷, YASUSHI HIRAMATSU⁸, Hisaji Oshima⁹, TOSHIHIKO MURAYAMA¹⁰, SHINJI HIGA¹¹, KAZUYA KURAOKA¹², FUMINORI HIRANO¹³, KENJI ICHIKAWA¹⁴, MITSUTOSHI KUROSAWA¹⁵, HIROAKI SUZUKI¹⁵, NORIYUKI CHIBA¹⁶, TAKAO SUGIYAMA¹⁷, YUKO MINAMI¹⁸, HITOSHI NIINO¹⁹, ATSUSHI IHATA²⁰, IKUO SAITO²¹, AKIKO MITSUO²², TOSHITAKA MAEJIMA²³, ATSUHIRO KAWASHIMA²⁴, HIROSHI TSUTANI²⁵, KOICHIRO TAKAHI²⁶, TAKAHIKO KASAI²⁷, YOKO SHINNO²⁸, YOSHIRO TACHIYAMA²⁹, NORIHIRO TERAMOTO³⁰, KENICHI TAGUCHI³¹, SHINJI NAITO³², SHIGERU YOSHIZAWA³³, MASAHIRO ITO³⁴, YASUO SUENAGA³⁵, Shunsuke Mori³⁶, SHOICHI NAGAKURA³⁷, NORIE YOSHIKAWA³⁸, MITSUHARU NOMOTO³⁹, ATSUHISA UEDA⁴⁰, SHOUHEI NAGAOKA⁴¹, YUKIO TSUURA⁴², KEIGO SETOGUCHI⁴³, SHOJI SUGII⁴⁴, Asami Abe⁴⁵, TOSHIAKI SUGAYA⁴⁶, HIROYUKI SUGAHARA⁴⁷, MASAHIRO KOSETO⁴⁸, YASUO KUNUGIZA², NORISHIGE IIZUKA³, RYOSUKE YOSHIHARA⁴, HIROKI YABE⁵, TOMOAKI FUJISAKI⁶, EIICHI MORII⁷, MORISHIGE TAKESHITA⁸, MASAKAZU SATO⁹, KAZUYOSHI SAITO¹⁰, Kiyoshi Matsui¹¹, YASUHIKO TOMITA¹², HIROSHI FURUKAWA¹³ and Shigeto Tohma¹⁴, ¹National Hospital Organization Osaka Minami Medical Center, Kawachinagano, Japan, ²Osaka Minami Medical Center, Kawachinagano City, Japan, ³National Hospital Organization (NHO), Osaka Minami Medical Center, Kawachinagano, Japan, ⁴Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-kofukai, Osaka, Japan, ⁵NHO Kyushu Medical Center, Fukuoka, Japan, ⁶National Hospital Organization, Nagoya Medical Center, Nagoya, JP, Nagoya, Japan, ⁷NHO Nagoya Medical Center, Nagoya, Japan, ⁸Japanese Red Cross Society Himeji Hospital, Himeji, Japan, ⁹National Tokyo Medical Center, Tokyo, Japan, ¹⁰NHO Kumamoto Medical Center, Kumamoto, Japan, ¹¹Daini Osaka Police Hospital, Osaka, Japan, ¹²NHO Kure Medical Center /Chugoku Cancer Center, Kure, Japan, ¹³NHO Asahikawa Medical Center, Asahikawa, Japan, ¹⁴Nissei hospital, Sapporo, Japan, ¹⁵NHO Hokkaido Cancer Center, Sapporo, Japan, ¹⁶NHO Morioka Medical Center, Morioka, Japan, ¹⁷NHO Shimoshizu Hospital, Yotsukaido, Japan, ¹⁸NHO Ibarakihigashi Hospital, Ibaraki, Japan, ¹⁹NHO Yokohama Medical Center, Yokohama, Japan, ²⁰National Hospital Organization Yokohama Medical Center, Yokohama, Japan, ²¹NHO Sagamihara Hospital, Sagamihara, Japan, ²²NHO Disaster Medical Center, Tachikawa, Japan, ²³NHO Shinshu Ueda Medical Center, Ueda, Japan, ²⁴NHO Kanazawa Medical Center, Kanazawa, Japan, ²⁵NHO Awara Hospital, Awara, Japan, ²⁶NHO Osaka Toneyama Medical Center, Toyonaka, Japan, ²⁷Japan Red Cross Society Tokushima Hospital, Komatsushima, Japan, ²⁸NHO Okayama Medical Center, Okayama, Japan, ²⁹NHO Hiroshima Nishi Medical Center, Otake, Japan, ³⁰NHO Shikoku Cancer Center, Matsuyama, Japan, ³¹NHO Kyushu Cancer Center, Fukuoka, Japan, ³²NHO Ureshino Medical Center, Ureshino, Japan, ³³NHO Fukuoka Hospital, Fukuoka, Japan, ³⁴NHO Nagasaki Medical Center, Omura, Japan, ³⁵NHO Beppu Medical Center, Beppu, Japan, ³⁶NHO Kumamoto Saishun Medical Center, Koshi, Japan, ³⁷NHO Kumamoto Minami Hospital, Uki, Japan, ³⁸NHO Miyakonojo Medical Center, Miyakonojo, Japan, ³⁹NHO Kagoshima Medical Center, Kagoshima, Japan, ⁴⁰Yokohama City University Medical Center, Yokohama, Japan, ⁴¹Yokohama Minami Kyosai Hospital, Yokohama, Japan, ⁴²Department of Pathology Yokosuka Kyosai Hospital, Yokosuka, Japan, ⁴³Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital / Tokyo Metropolitan Komagome Hospital, Tokyo, Japan, ⁴⁴Tokyo Metropolitan Matsuzawa Hospital, Tokyo, Japan, ⁴⁵Niigata Rheumatic Center, Shibata, Japan, ⁴⁶Fuchu Hospital, Izumi, Japan, ⁴⁷Sumitomo Hospital, Osaka, Japan, ⁴⁸Nippon Life Hospital, Osaka, Japan, ⁴⁹JCHO Hoshigaoka Medical Center, Hirakata, Japan, ⁵⁰Kishiwada City Hospital, Kishiwada, Japan, ⁵¹Hyogo Prefectural Kakogawa Hospital, Kakogawa, Japan, ⁵²Ako Central Hospital, Ako, Japan, ⁵³Matsuyama Red Cross Hospital, Matsuyama, Japan, ⁵⁴Osaka University, Suita, Japan, ⁵⁵Fukuoka University, Fukuoka, Japan, ⁵⁶Kurashiki University of Science and the Arts, Kurashiki, Japan, ⁵⁷University of Occupational and Environmental Health, Kitakyushu, Japan, ⁵⁸Hyogo Medical University, Nishinomiya, Japan, ⁵⁹International University of Health and Welfare, Otawara City, Japan, ⁶⁰NHO Tokyo National Hospital, Kiyose, Japan, ⁶¹NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: The largest multi-center collaborative study on lymphoproliferative disorders (LPD) in rheumatoid arthritis (RA) (RA-LPD) in Japan was conducted to characterize its clinical outcomes and…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].